NasdaqGS - Delayed Quote USD

Savara Inc. (SVRA)

4.7000 -0.1100 (-2.29%)
At close: April 22 at 4:00 PM EDT
Loading Chart for SVRA
DELL
  • Previous Close 4.8100
  • Open 4.8900
  • Bid 4.6700 x 200
  • Ask 4.7200 x 400
  • Day's Range 4.6900 - 5.0100
  • 52 Week Range 1.7700 - 5.7000
  • Volume 684,884
  • Avg. Volume 856,558
  • Market Cap (intraday) 649.296M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3300
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.79

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.

www.savarapharma.com

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SVRA

Performance Overview: SVRA

Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SVRA
0.00%
S&P 500
5.05%

1-Year Return

SVRA
161.11%
S&P 500
21.22%

3-Year Return

SVRA
147.37%
S&P 500
20.06%

5-Year Return

SVRA
49.57%
S&P 500
72.48%

Compare To: SVRA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SVRA

Valuation Measures

Annual
As of 4/22/2024
  • Market Cap

    650.68M

  • Enterprise Value

    514.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.64

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -8.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -23.32%

  • Return on Equity (ttm)

    -44.08%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -54.7M

  • Diluted EPS (ttm)

    -0.3300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    162.6M

  • Total Debt/Equity (mrq)

    19.01%

  • Levered Free Cash Flow (ttm)

    -28.37M

Research Analysis: SVRA

Analyst Price Targets

6.00
8.79 Average
4.7000 Current
16.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: SVRA

Fair Value

4.7000 Current
 

Dividend Score

0 Low
SVRA
Sector Avg.
100 High
 

Hiring Score

0 Low
SVRA
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
SVRA
Sector Avg.
100 High
 

Research Reports: SVRA

  • Daily – Vickers Top Buyers & Sellers for 01/02/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Insider Picks for 03/20/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/17/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     
  • Daily – Vickers Top Insider Picks for 03/16/2023

    The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.

     

People Also Watch